Well, this sure doesn't help

A bad day for pharma on the newswires:

Pfizer subsidiaries agree to pay $34.7 million in fines

Two subsidiaries of Pfizer Inc. have agreed to pay fines totaling $34.7 million for offering a kickback to recommend company drugs and for illegally promoting the human growth hormone product Genotropin for non-approved uses, federal prosecutors announced Monday. Prosecutors allege that Pharmacia & Upjohn Co. Inc. offered to overpay a subsidiary of a pharmacy benefit manager by $12.3 million in the hope the company would, in turn, recommend Pharmacia's drug products to its clients.

Pharmacy benefit managers act as middlemen between pharmaceutical companies and health insurers, often making product recommendations to health plans based on a drug's efficacy or cost-effectiveness.

Russia charges 3 doctors over Glaxo vaccine tests

The prosecutors said that starting in 2005 a hospital in Volgograd, 1,100 km (675 miles) southeast of Moscow, tested the vaccines on 112 children between one and two years of age without informing their parents first.

More like this

There's a phenomenon known as off-label prescribing. Basically, to prescribe something off-label is to prescribe it for an indication that is not FDA-approved but that is supported by considerable evidence. For example, it could involve using an FDA-approved drug for an indication that is not…
This was in the news a couple of weeks ago, but I held on to it so I could remind people of it again, the "too big to nail" syndrome": Imagine being charged with a crime, but an imaginary friend takes the rap for you. That is essentially what happened when Pfizer, the world's largest pharmaceutical…
Ten days ago Secretary of Health and Human Services Kathleen Sebelius announced that the US government was allocating $1 billion to help companies with production costs for a swine flu vaccine. Among the beneficiaries was French vaccine giant, Sanofi-Aventis, whose Sanofi Pasteur unit got a $190…
You can't make this stuff up. As PharmaGossip (among others, including the Times) reportst, a drug company pays $2.3 billion in fines to settle charges of unprecedented seriousness about practices that directly put patients at risk, and that came out of a four-year federal investigation. And some…